Hackensack Meridian Health to Pilot Combined Watson for Oncology and Cota Technology to Power Value-Based Clinical Decision Support in Cancer Care
IBM Watson Health, Cota and Hackensack Meridian Health have joined together to help oncologists make evidence- and outcomes-based clinical decisions for their cancer patients, which could reduce total cost of care.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
2 Clarke Drive Cranbury, NJ 08512